The Roche, Novartis and Kraft Group-backed cancer therapy developer raised $182m in an upsized IPO where it floated above its range.
C4 Therapeutics, a small molecule drug developer backed by diversified conglomerate Kraft Group and pharmaceutical firms Roche and Novartis, floated on Friday in a $182m initial public offering.
The company increased the number of shares in the offering from just over 8.8 million to 9.6 million and priced them at $19.00 each, above the IPO’s $16 to $18 range.
Founded in 2016, C4 is working on treatments for diseases such as cancer or neurodegenerative conditions by degrading and destroying…
